Reply: <sup>18</sup>F-FDG PET for Routine Posttreatment Surveillance in Oral and Oropharyngeal Squamous Cell Carcinoma

Krabbe, Christiaan A.; Pruim, Jan; Dijkstra, Pieter U.; Roodenburg, Jan

doi:10.2967/jnumed.110.075358

Cited by 7 publications

(2 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this way, SUV max is independent of ROI definition but more susceptible to artifacts such as noise [25]. Currently, SUV max is more commonly used than SUV mean , because it is less observer-dependent and more reproducible [24,26,27]. …”

Section: Suvmaxmentioning

confidence: 99%

FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma

Paidpally

Chirindel

Lam

et al. 2012

Imaging in Medicine

109

103

View full text Add to dashboard Cite

This article discusses the value of 18F-fluoro-2-deoxyglucose PET/CT imaging biomarkers in head and neck squamous cell carcinoma. 18F-fluoro-2-deoxyglucose PET/CT is valuable at baseline staging, radiotherapy planning, therapy response assessment and in the follow-up of patients with head and neck squamous cell carcinoma. Maximum and peak standardized uptake value (SUVmax and SUVpeak), metabolic tumor volume and total lesion glycolysis are the common 18F-fluoro-2-deoxyglucose quantitative parameters that have been studied, along with qualitative assessments. These parameters will be evaluated with respect to their established or potential role as noninvasive biomarkers for patient risk stratification, treatment response and survival outcome.

show abstract

Section: Suvmaxmentioning

confidence: 99%

FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma

Paidpally

Chirindel

Lam

et al. 2012

Imaging in Medicine

109

103

View full text Add to dashboard Cite

show abstract

“…Monitoring of early response during treatment could allow treatment modification or adaptation and this has been shown in a proof-of-principle study by Geets et al 41 Several published studies have demonstrated this role using baseline 18F-FDG-PET parameters, [42][43][44][45][46][47][48][49] or 18F-FDG-PET imaging acquired 2-4 months following completion of treatment. [50][51][52][53] The optimum timing of 18F-FDG-PET imaging following treatment is uncertain due to 18F-FDG uptake in non-malingnant inflammatory tissue which complicates interpretation. 54 Several studies have shown that the level of hypoxia depicted by 18F-FMISO PET before treatment correlates with loco-regional failure.…”

Section: Pet-image As a Biomarker With Prognostic And/or Predictive Vmentioning

confidence: 99%